Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riviciclib in Cyclin D1+ Advanced Melanoma
NCT00835419Phase 2Completed
- Sponsor
- Piramal Enterprises Limited
- Start
- May 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of P276 in Malignant Melanoma (MM), sponsored by Piramal Enterprises Limited. Primary endpoint: Progression Free Survival rate at Day 168. Started May 2009; status: completed.
02
Drugs
P276
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00835419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00835419.